CURRENT USE AND OUTCOMES OF CELLULAR THERAPY: BRAZILIAN SUMMARY SLIDES -2025

Chimeric antigen receptor T-cells (CAR T cells) are genetically modified cellular immunotherapies approved as a standard of care treatment for patients with lymphoma and leukemia worldwide. Here, we report the initial activity in Brazilian centers through the collaboration between the Brazilian Cellular Therapy and Bone Marrow Transplant Society (SBTMO) and the Center for International Blood and Marrow Transplant Research (CIBMTR). A total of 104 patients who received commercial and academic CAR-T cells in Brazil between January 2020 and April 2025 were included. The median age was 56 years (range 4-83). Indications were Non-Hodgkin Lymphoma (NHL; 75 cases; 72%), Acute Lymphoblastic Leukemia (ALL; 23 cases; 22%), Multiple Myeloma (MM; 4 cases; 4%) and Chronic lymphoblastic leukemia (CLL; 2 cases; 2%). Anti-CD19 commercial CAR-T were 82% of the total, 68 for NHL and 17 for ALL). Most deaths were due to disease progression or relapse (n=19), followed by infections (n=8). The overall survival after a median follow-up of 200 days was 73% (95% CI: 62-86; N=63) for NHL and 79% (95% CI: 63-99; N=19) for ALL. This report demonstrates the successful initial implementation of CAR-T cells in Brazil among centers that report to the SBTMO/CIBMTR. This infrastructure will assist in further capturing the activity, assessing the outcomes, and complying with regulatory requirements.

Authors

Institutions

Publication Details

Journal
JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY
Published
2025-07-04
DOI
https://doi.org/10.46765/2675-374x.2025v6n1p271
Citations
1
Primary Topic
Biomedical Ethics and Regulation
Type
article
Field-Weighted Citation Impact
1.16
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

CURRENT USE AND OUTCOMES OF CELLULAR THERAPY: BRAZILIAN SUMMARY SLIDES -2025

Paula Moreira da Silva Sabaini, Monique Ammi, Vanderson Rocha, Vaneuza Araújo Moreira Funke et al.
1 citations
JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY
Biomedical Ethics and Regulation
1.16
article

CURRENT USE AND OUTCOMES OF CELLULAR THERAPY: BRAZILIAN SUMMARY SLIDES -2025

Paula Moreira da Silva Sabaini, Monique Ammi, Vanderson Rocha, Vaneuza Araújo Moreira Funke, Flavia Ferreira da Costa, Carmem Bonfim, Fernando Barroso Duarte, Jayr Schmidt Filho, Ricardo Chiattone, Phillip Scheinberg, Celso Arrais‐Rodrigues, Anderson João Simione, Rosana Rocha Concilio, Antônio Vaz de Macedo, Adriana Seber, Nelson Hamerschlak, Cilmara Kuwahara, Adriana Mendes de Quadros Cavilha, Joaquim Gasparini dos Santos, Lúcia Mariano da Rocha Silla, Leonardo Javier Arcuri, Lucila Nassif Kerbauy, Yana Novis, Heliz Regina A. Neves, Marco Aurélio Salvino, Marcelo C. Pasquini, Andreza Alice Feitosa Ribeiro, Cinthya Corrêa da Silva
article en
1 citations

Abstract

Chimeric antigen receptor T-cells (CAR T cells) are genetically modified cellular immunotherapies approved as a standard of care treatment for patients with lymphoma and leukemia worldwide. Here, we report the initial activity in Brazilian centers through the collaboration between the Brazilian Cellular Therapy and Bone Marrow Transplant Society (SBTMO) and the Center for International Blood and Marrow Transplant Research (CIBMTR). A total of 104 patients who received commercial and academic CAR-T cells in Brazil between January 2020 and April 2025 were included. The median age was 56 years (range 4-83). Indications were Non-Hodgkin Lymphoma (NHL; 75 cases; 72%), Acute Lymphoblastic Leukemia (ALL; 23 cases; 22%), Multiple Myeloma (MM; 4 cases; 4%) and Chronic lymphoblastic leukemia (CLL; 2 cases; 2%). Anti-CD19 commercial CAR-T were 82% of the total, 68 for NHL and 17 for ALL). Most deaths were due to disease progression or relapse (n=19), followed by infections (n=8). The overall survival after a median follow-up of 200 days was 73% (95% CI: 62-86; N=63) for NHL and 79% (95% CI: 63-99; N=19) for ALL. This report demonstrates the successful initial implementation of CAR-T cells in Brazil among centers that report to the SBTMO/CIBMTR. This infrastructure will assist in further capturing the activity, assessing the outcomes, and complying with regulatory requirements.

JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPYVol. 6(1)
Universidade Federal da Bahia (BR), Universidade Federal do Rio Grande do Sul (BR), Universidade Federal Fluminense (BR), Medical College of Wisconsin (US), Hospital Israelita Albert Einstein (BR), AC Camargo Hospital (BR), Hospital de Câncer de Barretos (BR), Hospital de Clínicas de Porto Alegre (BR), Hospital Samaritano de São Paulo (BR), Hospital Universitário Walter Cantídio (BR), Hospital Nossa Senhora das Graças (BR), Associação de Assistência à Criança Deficiente (BR), Hospital IPO (BR), Hospital Amaral Carvalho (BR), Beneficência Portuguesa de São Paulo (BR), Versiti Blood Center of Wisconsin (US), Hospital Central da Polícia Militar (BR), Hospital de Clínicas Universidade Federal do Paraná (BR), Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (BR), Hospital Sírio-Libanês (BR), National Institute Of Blood Disease and Bone Marrow Transplantation (PK), Universidade Federal de São Paulo (BR)
Openalex Percentile: Top 20%
Biomedical Ethics and Regulation
1.16
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.